Synthesize Bio’s successful $10 million seed round underscores the growing demand for advanced tools in generative genomics, a critical area for biopharmaceutical innovation. This funding will significantly enhance their capabilities, enabling researchers to simulate gene expression outcomes more effectively and ultimately accelerating drug development.
SEATTLE–(BUSINESS WIRE)–Synthesize Bio, a biotechnology company pioneering biological foundation models to simulate the results of gene expression experiments, today announced a $10 million seed round led by Madrona, with participation from Sahsen Ventures, Inner Loop Capital, Point Field Partners, and AI2 Incubator. The funding will accelerate the development of Synthesize Bio’s generative genomics models and expand access for biopharmaceutical companies and researchers. “Biopharma companies
Source: Original Press Release
